Physician profile
Jenna Simon
NPI 1477138832
$11,264.71
in general payments reported to CMS, 2019-2025
55 companies · $2,750 in 2025
The $2,750 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $980 · 2023: $5,560 · 2024: $1,974 · 2025: $2,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,385 · Travel and Lodging: $797 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,384.65 |
| Travel and Lodging | $796.66 |
| Education | $102.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $1,594.43 | 2024-2025 | Remodulin, Orenitram, Remodulin |
| Emd Serono, INC. | $1,122.39 | 2022-2024 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,044.66 | 2022-2025 | Kesimpta |
| Alexion Pharmaceuticals, INC. | $619.86 | 2022-2024 | Ultomiris, Soliris |
| Genentech USA, INC. | $430.40 | 2022-2024 | Ocrevus, Enspryng |
| Mallinckrodt Hospital Products INC. | $408.63 | 2022-2024 | Acthar |
| Genzyme Corporation | $356.65 | 2022-2023 | |
| Biogen, INC. | $353.74 | 2022-2024 | Vumerity, Tysabri |
| Celgene Corporation | $350.17 | 2022-2024 | Zeposia |
| Ucb, INC. | $348.39 | 2022-2024 | Briviact, Nayzilam, Rystiggo |
| Pfizer INC. | $310.51 | 2023-2024 | |
| Tg Therapeutics, INC. | $304.55 | 2023-2024 | |
| Abbvie INC. | $278.35 | 2022-2024 | |
| Amgen INC. | $275.29 | 2022-2025 | Repatha, Aimovig |
| Merck Sharp & Dohme LLC | $252.71 | 2024-2025 | Winrevair, Verquvo |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $190.17 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Genentech, INC. | $177.70 | 2023-2024 | Ocrevus, Tnkase |
| Biohaven Pharmaceutical Holding Company Ltd. | $159.60 | 2022 | |
| Lilly USA, LLC | $156.40 | 2023-2024 | Emgality, Amyvid, Reyvow |
| Csl Behring | $156.22 | 2022-2024 | Hizentra |
| Axsome Therapeutics, INC. | $156.15 | 2023-2024 | Sunosi |
| Abiomed | $149.66 | 2025 | |
| Shockwave Medical, INC | $149.22 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $148.70 | 2025 | Opsumit, Uptravi |
| Recor Medical INC | $144.87 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $144.71 | 2025 | Corevalve Evolut R |
| Neurocrine Biosciences, INC. | $140.15 | 2023 | Ongentys, Ingrezza |
| Philips North America LLC | $136.99 | 2025 | Igt Devices Undivided |
| E.R. Squibb & Sons, L.L.C. | $125.36 | 2024 | Camzyos |
| Amneal Pharmaceuticals LLC | $103.98 | 2022-2023 | Lyvispah, Rytary |
| Horizon Therapeutics Plc | $85.79 | 2023 | Uplizna |
| Acorda Therapeutics, INC | $80.82 | 2022-2023 | Ampyra |
| Lundbeck LLC | $78.30 | 2023 | Vyepti |
| Boston Scientific Corporation | $73.65 | 2025 | Watchman |
| Astrazeneca Pharmaceuticals Lp | $65.08 | 2022-2024 | Wainua |
| Sk Life Science, INC. | $61.67 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $57.12 | 2023-2024 | Dysport |
| Teva Pharmaceuticals USA, INC. | $54.52 | 2022-2023 | Austedo, Austedo Xr |
| Grifols USA, LLC | $49.86 | 2024 | Gamunex-C |
| Banner Life Sciences, LLC | $40.18 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $38.49 | 2023 | Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2024 | Jardiance |
| Eisai INC. | $32.09 | 2022 | |
| Esperion Therapeutics, INC. | $26.47 | 2025 | Nexletol |
| Impel Pharmaceuticals INC. | $24.95 | 2023 | Trudhesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.59 | 2025 | Lifevest |
| Ani Pharmaceuticals, INC. | $19.00 | 2024 | Purified Cortrophin Gel |
| Neurelis, INC. | $18.56 | 2023 | Valtoco |
| Avion Pharmaceuticals | $18.20 | 2023 | Dhivy |
| Azurity Pharmaceuticals, INC. | $16.71 | 2023 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2023 | Relistor |
| Idorsia Pharmaceuticals US INC | $15.55 | 2023 | Quviviq |
| Corium, LLC | $14.12 | 2023 | Adlarity |
| Acadia Pharmaceuticals INC | $13.86 | 2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.